By James Hitchen, patent attorney, HGF
Artificial intelligence is changing the balance of value within the medtech sector.
Historically, competitive advantage was often tied to hardware engineering, manufacturing capability, or regulatory know-how.
Today, however, an increasing proportion of that value sits within software-driven functionality: the ability to process clinical data more effectively, generate faster or more accurate outputs, and improve decision-making within healthcare environments.
As AI becomes embedded across diagnostics, monitoring systems, imaging platforms, and connected devices, many medtech companies are finding that their most commercially significant innovations are no longer purely physical products.
They are proprietary technical solutions built around data, algorithms, and system integration.
In that environment, intellectual property becomes more than a legal safeguard.
It becomes a mechanism for protecting a company’s commercial position in markets where technological advances can otherwise be replicated quickly.
AI in medtech
One of the defining characteristics of AI innovation is that barriers to entry are often lower than businesses initially expect.
Access to machine learning frameworks, computing infrastructure, and even sophisticated foundation models is becoming increasingly widespread.
This means that the long-term value of an AI-enabled medtech product rarely lies in the existence of AI itself. It lies in the way the technology has been applied to solve a specific technical or clinical problem.
That distinction matters commercially.
A company that develops an AI-enabled imaging platform capable of improving diagnostic confidence is not simply offering “AI”.
It is offering a specific technical implementation that may improve image quality, reduce analysis time, or support more reliable clinical interpretation.
Those are commercially valuable outcomes, and they are often precisely the areas where meaningful intellectual property protection can be secured.
Protecting innovation
For medtech businesses, a well-structured patent portfolio can therefore create a level of protection around the practical application of innovation, rather than around abstract concepts. In sectors where product differentiation can narrow rapidly, this can become a major strategic advantage.
Strong intellectual property protection can also alter the dynamics of competition.
Competitors may be able to develop similar functionality eventually, but patents can increase the time, cost, and complexity involved in doing so.
That additional commercial friction matters. It can create space for market penetration, strengthen pricing power, and support customer retention during critical growth phases.
Investor readiness
The value of IP also extends well beyond direct market exclusivity.
Investors increasingly consider whether medtech companies genuinely own defensible technology.
In AI-driven markets, this distinction is becoming more important.
Companies that can demonstrate ownership of protected technical innovation are often viewed as more resilient and strategically valuable than those relying solely on execution speed.
This is particularly relevant because AI markets evolve quickly.
Technical advantages that appear significant today may quickly lose impact. Intellectual property can help extend the commercial lifespan of innovation by protecting the specific methods, architectures, or technical approaches that underpin product performance and form the basis for later innovations.
A strong IP position can also influence how a company is perceived during acquisition discussions or strategic partnerships.
Acquirers are rarely interested only in current revenues. They are often assessing whether a company possesses protected technology that competitors cannot easily reproduce. In many transactions, the value attributed to intellectual property extends far beyond the cost of obtaining the patents themselves.
For growing medtech businesses, this can create a compounding effect. Protected innovation can support investment.
Investment enables further development. Continued innovation strengthens the portfolio.
Over time, the intellectual property itself can become a strategic asset that shapes the company’s market position and negotiating leverage.
Importantly, many of the most valuable AI-related inventions in medtech are not always immediately recognised as such internally.
Businesses often focus on headline functionality while overlooking the technical advances that make that functionality commercially viable.
Improvements relating to signal processing, data handling, workflow integration, device performance, or reliability may all contribute significantly to product differentiation.
In regulated healthcare environments, even relatively subtle technical improvements can carry substantial commercial importance.
IP Strategy
This is why timing and strategy are critical.
Companies that treat intellectual property as a late-stage legal process may miss opportunities to protect innovations that ultimately become central to product value.
By contrast, businesses that integrate IP considerations into product development earlier are often better positioned to identify and secure commercially meaningful protection before innovations enter the public domain.
The quality of the strategy also matters as much as the number of filings.
A large portfolio with weak commercial alignment may offer limited practical value.
Effective AI-focused patent strategies are typically built around protecting the technical features most likely to influence purchasing decisions, clinical adoption, or future scalability.
The objective is not simply to accumulate patents, but to secure protection around the areas of innovation that competitors would most want to replicate.
In the medtech sector, this increasingly requires a sophisticated understanding of both technology and commercial positioning.
AI-related inventions often sit at the intersection of software, hardware, data science, and clinical application.
Capturing their value effectively requires patent strategies that reflect how the technology functions in practice and where competitive differentiation genuinely exists.
Similarly, inventing on top of competitor products can be a highly effective strategy to block commercialisation of rival products or to secure favourable cross-licences.
It can even be used as a strategy by start-ups aiming to be acquired by a larger company, whereby a situation is created where the most efficient solution for an established player in the market looking to advance into a new technology area is simply to buy an SME operating in this space, rather than to try and design around or knock out the SME’s IP.
Match your IP Strategy to your AI-focussed innovation
As AI continues to reshape the industry, the gap between companies that develop innovation and companies that successfully protect it is likely to widen.
Technical capability alone is unlikely to guarantee long-term advantage in markets where innovation cycles move rapidly and competitive pressure remains high.
For medtech companies, intellectual property is becoming a central component of commercial strategy.
A well-developed IP portfolio can protect differentiation, strengthen investor confidence, improve strategic leverage, and help transform technical innovation into durable enterprise value.
In the age of AI, that protection may become one of the most important assets a medtech business owns.
The HGF medtech and digital health team has extensive experience drafting robust patent applications in the medtech AI space, with industry-leading expertise in drafting and prosecuting around the strict UK and European sufficiency, excluded subject-matter and inventive step requirements that typically cause difficulty for Applicants in this field.
Moreover, the team takes pride in delivering comprehensive full-cycle IP strategies, from invention capture to enforcement, tailored to every business’s commercial objectives in the medtech AI space.
Find out more about HFG at hgf.com
